A Phase III Open-Label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-Small Cell Lung Cancer That Has Progressed After a Platinum-Containing Doublet
收藏DataCite Commons2026-04-29 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00013053/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet.
提供机构：
Vivli
创建时间：
2026-04-29
